title: Protection of CHO cells by transfer of survivin driven by ovarian-specific promoter OSP-2.
abstract: Chemotherapy is the major therapy for cancer in clinic. However, chemotherapeutic agents can harm the other tissues/organs besides cancer. Thus, there are great interests in protecting the innocents by the transfer of protective genes. There are two problems to be solved, one is the selection of protective genes and the other is the orientation of the exotic genes. Recent researches demonstrated that the principal mechanism of chemotherapeutics was through apoptosis. Hereby, introduction of anti-apoptosis genes might interrupt the processes of apoptosis to avoid side effect from chemotherapeutics. On the other hand, tissue-specific promoters, which control gene expression in a tissue-specific manner, might be an alternative tool to guarantee the location of target genes. In this research, we applied gene therapy to chemoprotection using anti-apoptosis gene survivin and ovarian-specific promoter OSP-2. The results showed that OSP-2 could specifically drive the expression of survivin in ovarian cells and survivin could protect cells via inhibiting apoptosis. This might put a light on the future of chemoprotective gene therapy.
authors.affiliation: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanchang University, No. 17 Yongwaizheng Street, Nanchang, 330006, China. gyntuzi@126.com
authors.forename: Chun-Hua
authors.initials: CH
authors.lastname: Tu
authors.forename: Wei-Peng
authors.initials: WP
authors.lastname: Liu
authors.forename: Mei
authors.initials: M
authors.lastname: Dong
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Cai
authors.forename: Ya-Qin
authors.initials: YQ
authors.lastname: Mo
authors.forename: Dong-Zi
authors.initials: DZ
authors.lastname: Yang
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins / Q000008:administration & dosage* / Q000235:genetics; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D064420:Drug-Related Side Effects and Adverse Reactions; D005434:Flow Cytometry; D018390:Gene Targeting / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy*; D011401:Promoter Regions, Genetic / Q000235:genetics; D000077022:Survivin; D013778:Tetrazolium Salts; D013844:Thiazoles; D014162:Transfection
chemical_list: D051017:Apoptosis Regulatory Proteins; C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin; D013778:Tetrazolium Salts; D013844:Thiazoles; C022616:thiazolyl blue